Dr Stock Pick HOT News & Alerts!
_________________________________________
FREE Daily Stock Alerts From DrStockPick.com
_________________________________________
Monday September 21, 2009
DrStockPick.com Stock Report!
CSCO, PWRM, CVAT, CSRH, PER, ABT
CSCO, Cisco Systems, Inc.
CSCO designs, manufactures, and sells Internet Protocol (IP)-based networking and other products to the communications and IT industry worldwide.
Pelco by Schneider Electric, and CSCO today announced a strategic technology agreement to pursue the joint development of new high-definition (HD) Internet Protocol (IP) video security cameras built upon Pelco’s award-winning Sarix(TM) technology platform. The new co-branded video security cameras will bring together Pelco’s leadership in imaging with Cisco’s IP networking expertise to deliver the next generation of high-definition IP video security cameras. These cameras will be sold globally by CSCO Authorized Technology Providers and are currently projected to be available from the end of 2009.
PWRM, Power 3 Medical Products Inc, PWRM.OB
Power3 Medical Products, Inc. is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3�s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro). Power3 expects to complete phase II clinical validation trials of its blood serum diagnostics for Alzheimer�s disease (NuroPro-AD), and Parkinson�s disease (NuroPro-PD) in 2009 and for breast cancer in 2010, followed by filings with the FDA. Power3 operates a state-of-the-art CLIA certified laboratory in The Woodlands (Houston), Texas. Power3 continues to evolve and enhance its IP portfolio, employing sensitive and specific combinations of biomarkers it has discovered from a broad range of diseases as the basis of highly selective blood-based tests for ALS, Alzheimer�s, and Parkinson�s diseases, and breast cancer.
PWRM Announced that its Chief Scientific Officer is Chair and Keynote Speaker of Session at the BTI Life Sciences 2nd Annual Congress and Expo of Molecular Diagnostics in Beijing, China in November 2009
Further international recognition of validity as the company�s President and CSO, Dr. Ira Goldknopf will deliver an invited Keynote address and chair a session on �Biomarkers and Diagnostics in Personalized Medicine (Track 6-4),� at the BIT Life Sciences 2nd International Congress and Expo of Molecular Diagnostics in Beijing, China, November 19-21, 2009. The Theme of the meeting is �New Leadership of Personalized Medicine.�
More about PWRM at www.power3medical.com
CVAT, Cavitation Technologies Inc, CVAT.OB
CVAT is a �Green-Tech� company, established in 2006 to become a world leader in the development of new cutting edge technologies for the, vegetable oil refining, renewable fuel, petroleum, water treatment, wastewater sanitation, petroleum, food and beverage, chemical industries.
CVAT has been chosen as one of the �50 Hottest Companies in Bioenergy� by Biofuels Digest, the most widely read biofuels daily publication in the world.
The stimulus bill has allocated $49.7 billion toward green energy technology. A lot of money is earmarked for renewable energy projects.
CVAT has entered into an agreement with Desmet Ballestra Group www.desmetballestra.com (the market leaders in the field of the extraction and refining of oils and fats from oleaginous materials and the conversion of crude oils and fats into value-added products such as edible oil, shortening, biodiesel, detergents, surfactants and soap) to evaluate CVAT’s Nano Cavitation Reactor technology and its potential benefits to the vegetable oil industry.
More about CVAT at www.cavitationtechnologies.com
CSRH, Consorteum Holdings Inc, CSRH.OB
CSRH is a company in the financial services, payment and transaction processing industries.
CSRH provides electronic transaction processing and management services to financial institutions, healthcare, government, public and private sector companies. CSRH’s services provide customized, innovative technology solutions that create, augment and enhance customers� existing financial, payment and transactional processing systems.
CSRH has established a new Joint Venture partnership with Chicago based, Trans Screen Group of Illinois. Under the terms of the joint venture, Trans Screen will leverage Consorteum Holdings expertise to provide financial services solutions to a number of new emerging global markets.
Trans Screen Group and CSRH will expand into markets outside North America to include new business opportunities in India, Africa, Russia, Latin America, Thailand and China for payroll cards, loyalty programs, gift cards, processing and other value added services. Initial endeavors will be announced in Q4, 2009 with deployments expected to commence in early 2010.
More about CSRH at www.consorteum.com
PER, Perot Systems Corp.
PER provides information technology services and business solutions worldwide. It offers infrastructure, applications, business process, and consulting services.
Dell Inc. will spend $3.9 billion for the technology services company PER (it will offer $30 per share in cash). in an attempt to expand beyond the PC business and compete more aggressively with Hewlett-Packard Co. — which recently bought another tech-services company founded by H. Ross Perot.
ABT, Abbott Laboratories
ABT is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics.
Long-term data presented today from the SPIRIT III pivotal U.S. clinical trial demonstrated that the observed clinical advantages of ABT’s market-leading XIENCE V� Everolimus Eluting Coronary Stent System continued to increase as compared to the TAXUS� Express2 Paclitaxel-Eluting Coronary Stent System (TAXUS). At three years, XIENCE V demonstrated a 43 percent reduction in the risk of major adverse cardiac events (MACE) compared to TAXUS (9.1 percent for XIENCE V vs. 15.7 percent for TAXUS, p-value=0.003). MACE is an important composite clinical measure of safety and efficacy outcomes for patients, defined as cardiac death, heart attack (myocardial infarction or MI), or ischemia-driven target lesion revascularization (ID-TLR driven by lack of blood supply). The three-year results from the SPIRIT III trial will be presented today by Gregg W. Stone, M.D., professor of medicine at Columbia University Medical Center, during the 2009 Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco.
Keep a close eye on CSCO, PWRM, CVAT, CSRH, PER and ABT, do your homework, and like always BE READY for the ACTION!
No comments:
Post a Comment